Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors

Stephen Connelly, David E. Mortenson, Sungwook Choi, Ian A. Wilson, Evan T. Powers, Jeffery W. Kelly, Steven Johnson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state—thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.

Original languageEnglish (US)
Pages (from-to)3441-3449
Number of pages9
JournalBioorganic and Medicinal Chemistry Letters
Volume27
Issue number15
DOIs
StatePublished - 2017

Fingerprint

Prealbumin
Familial Amyloid Neuropathies
Agglomeration
South America
Controlled Clinical Trials
Medical Genetics
Molecules
Kinetics
Structure-Activity Relationship
Cardiomyopathies
Thyroxine
Neurology
Computer Simulation
Pathology
Oral Administration
Amyloid
Japan
Central Nervous System
Placebos
Monomers

Keywords

  • Amyloid
  • Familial amyloid polyneuropathy
  • In silico docking
  • Inhibitor
  • Prediction algorithms
  • Senile systemic amyloidosis
  • Structural biology
  • Structure-based drug design
  • Thyroid hormone receptors
  • Transthyretin
  • TTR

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. / Connelly, Stephen; Mortenson, David E.; Choi, Sungwook; Wilson, Ian A.; Powers, Evan T.; Kelly, Jeffery W.; Johnson, Steven.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 27, No. 15, 2017, p. 3441-3449.

Research output: Contribution to journalArticle

Connelly, Stephen ; Mortenson, David E. ; Choi, Sungwook ; Wilson, Ian A. ; Powers, Evan T. ; Kelly, Jeffery W. ; Johnson, Steven. / Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. In: Bioorganic and Medicinal Chemistry Letters. 2017 ; Vol. 27, No. 15. pp. 3441-3449.
@article{0126217b597446d1bd642751b17f162c,
title = "Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors",
abstract = "Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state—thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.",
keywords = "Amyloid, Familial amyloid polyneuropathy, In silico docking, Inhibitor, Prediction algorithms, Senile systemic amyloidosis, Structural biology, Structure-based drug design, Thyroid hormone receptors, Transthyretin, TTR",
author = "Stephen Connelly and Mortenson, {David E.} and Sungwook Choi and Wilson, {Ian A.} and Powers, {Evan T.} and Kelly, {Jeffery W.} and Steven Johnson",
year = "2017",
doi = "10.1016/j.bmcl.2017.05.080",
language = "English (US)",
volume = "27",
pages = "3441--3449",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors

AU - Connelly, Stephen

AU - Mortenson, David E.

AU - Choi, Sungwook

AU - Wilson, Ian A.

AU - Powers, Evan T.

AU - Kelly, Jeffery W.

AU - Johnson, Steven

PY - 2017

Y1 - 2017

N2 - Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state—thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.

AB - Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state—thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.

KW - Amyloid

KW - Familial amyloid polyneuropathy

KW - In silico docking

KW - Inhibitor

KW - Prediction algorithms

KW - Senile systemic amyloidosis

KW - Structural biology

KW - Structure-based drug design

KW - Thyroid hormone receptors

KW - Transthyretin

KW - TTR

UR - http://www.scopus.com/inward/record.url?scp=85020797205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020797205&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2017.05.080

DO - 10.1016/j.bmcl.2017.05.080

M3 - Article

VL - 27

SP - 3441

EP - 3449

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 15

ER -